Introduction {#section5-1756284819881302}
============

Hepatic encephalopathy (HE) is a common and serious complication of end-stage liver disease.^[@bibr1-1756284819881302]^ It is divided into covert and overt HE according to the clinical manifestations and severity of HE. The incidence of overt and covert HE during the clinical course of liver cirrhosis is 30--40% and 20--80%, respectively.^[@bibr1-1756284819881302]^ The risk of death in liver cirrhosis is greatly increased by the occurrence of HE which exerts a huge burden on patients, caregivers, and healthcare systems.^[@bibr2-1756284819881302]^

Except for the well-known drugs, such as lactulose,^[@bibr3-1756284819881302]^ rifaximin,^[@bibr4-1756284819881302]^ L-ornithine-L-aspartate,^[@bibr5-1756284819881302]^ probiotics,^[@bibr6-1756284819881302]^ and zinc,^[@bibr7-1756284819881302]^ the role of human albumin (HA) infusion for the management of HE has been widely and increasingly recognized, but remains controversial.^[@bibr8-1756284819881302][@bibr9-1756284819881302]--[@bibr10-1756284819881302]^ Recently, an Italian multicenter trial (ANSWER) found that long-term HA administration to patients with decompensated cirrhosis significantly reduced the incidence of grade 3--4 HE.^[@bibr11-1756284819881302]^ The Italian Association for the Study of the Liver (AISF) practice guideline also suggested that HA infusion could decrease the incidence of type C overt HE in cirrhotic patients with ascites.^[@bibr12-1756284819881302]^ By comparison, the AASLD-EASL practice guideline did not recommend HA infusion for the management of HE.^[@bibr1-1756284819881302]^ The inconsistence of recommendations among these societies may be because the potential mechanism of HA infusion in the prevention and treatment HE is elusive and the current evidence is conflicting among the published clinical studies. In the study by Simón-Talero and colleagues,^[@bibr8-1756284819881302]^ which included patients with a mean serum albumin (ALB) level of 30 g/l, the effect of HA infusion was not significant. On the contrary, in the Sharma and coworkers' study,^[@bibr9-1756284819881302]^ which included patients with a mean serum ALB level of nearly 24 g/l, the effect of HA infusion was significant. Therefore, one may speculate that the difference in patients' serum ALB levels led to the heterogeneity in the effect of HA infusion on the development and prognosis of HE.

In the present study, we aimed to explore the association of serum ALB level with the incidence and mortality of overt HE in cirrhotic patients during hospitalization.

Methods {#section6-1756284819881302}
=======

Study design {#section7-1756284819881302}
------------

This study protocol was approved by the Medical Ethical Committee of the General Hospital of Northern Theater Command (formerly called as General Hospital of Shenyang Military Area), with approval no. k(2019)18 (ethical approval was obtained on 5 June 2019). The requirement of informed written consent was waived because we only extracted the data from the inpatients' medical records. The source of our patients comprised two major parts: the first part was a cohort which retrospectively enrolled the patients with liver cirrhosis, without malignancy, consecutively admitted to our hospital from January 2010 to June 2014; the second part was a cohort which prospectively enrolled the patients with liver cirrhosis, without malignancy, consecutively admitted to the Department of Gastroenterology of our hospital and underwent contrast-enhanced computed tomography and upper gastrointestinal endoscopy from December 2014 to February 2019.^[@bibr13-1756284819881302]^ All patients were screened for eligibility. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

As for the association of serum ALB level with development of HE during hospitalizations, the exclusion criteria were as follows: (a) patients with overt HE at admission; (b) patients who received HA infusion before diagnosis of overt HE during hospitalizations; (c) patients who were not diagnosed with overt HE but received HA infusion during hospitalization; and (d) patients in whom serum ALB level was missing.

As for the association of serum ALB level with in-hospital mortality of HE, the exclusion criteria were as follows: (a) patients without overt HE at admission; (b) patients who received HA infusion during hospitalizations; and (c) patients in whom serum ALB level was missing.

Data collection {#section8-1756284819881302}
---------------

Data were collected as follows: age, sex, etiology of liver cirrhosis, ascites, acute upper gastrointestinal bleeding (AUGIB), infection, hemoglobin (Hb), white blood cell count (WBC), platelet count (PLT), total bilirubin (TBIL), ALB, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AKP), gamma-glutamyl transpeptidase (GGT), blood urea nitrogen (BUN), serum creatinine (Scr), potassium (K), sodium (Na), ammonia, prothrombin time (PT), and activated partial thromboplastin time (APTT). Child--Pugh and model for end-stage liver disease (MELD) scores were calculated.^[@bibr14-1756284819881302]^ We recorded the overt HE events at admission or during hospitalization and re-evaluated the diagnosis of overt HE according to the current guideline.^[@bibr1-1756284819881302]^ In-hospital death was also recorded.

Statistical analysis {#section9-1756284819881302}
--------------------

All statistical analyses were performed using the SPSS software version 20.0 (IBM Corp, Armonk, NY, USA) and MedCalc software version 11.4.2.0 (MedCalc Software, Mariakerke, Belgium). A two-tailed *p* \< 0.05 was considered statistically significant. Logistic regression analysis was performed to identify the independent predictors associated with the development of, and in-hospital death from, overt HE. Receiver operator characteristic (ROC) curve analysis was used to explore the performance of serum ALB level for predicting the development of, and in-hospital death from, overt HE. Area under curve (AUC) was calculated. The best cut-off value with its sensitivity and specificity was also identified. Then, we divided the patients into high- and low-serum-ALB-level groups according to the best cut-off value. Difference between high- and low-serum-ALB-level groups was compared by the nonparametric Mann--Whitney *U* test and the Chi-square test. The cumulative rates of overt HE and its associated mortality during hospitalization were further assessed with the Kaplan--Meier curve analyses, and the difference between the groups divided according to the best cut-off value was compared by the log-rank test.

Results {#section10-1756284819881302}
=======

Association of serum ALB level with development of overt HE during hospitalizations {#section11-1756284819881302}
-----------------------------------------------------------------------------------

A total of 2376 cirrhotic patients were included ([Figure 1](#fig1-1756284819881302){ref-type="fig"}). Baseline characteristics were described in [Table 1](#table1-1756284819881302){ref-type="table"}. Median age was 55.26 years (range: 6.20--89.19), and 1619 (68.10%) patients were male. Median serum ALB level was 34.90 g/l (range: 9.60--56.20). Median Child--Pugh and MELD scores were 6 (range: 5--13) and 5.32 (range: --9.67--38.80), respectively. Among them, 113 (4.80%) patients developed overt HE during hospitalizations.

![Flow chart of patient selection.\
ALB, albumin; HE, hepatic encephalopathy.](10.1177_1756284819881302-fig1){#fig1-1756284819881302}

###### 

Incidence of overt HE: difference between high-ALB-level (\>31.6 g/l) and low-ALB-level (⩽31.6 g/l) groups.

![](10.1177_1756284819881302-table1)

  Variables                    Patients, *n*   Overall[\*](#table-fn11-1756284819881302){ref-type="table-fn"}   Patients, *n*   ALB \> 31.6g/l group[\*](#table-fn11-1756284819881302){ref-type="table-fn"}   Patients, *n*   ALB ⩽ 31.6 g/l group[\*](#table-fn11-1756284819881302){ref-type="table-fn"}   *p* value
  ---------------------------- --------------- ---------------------------------------------------------------- --------------- ----------------------------------------------------------------------------- --------------- ----------------------------------------------------------------------------- -------------
  Age, years                   2376            55.26 (6.20--89.19) 55.27 ± 12.08                                1638            57.63 (6.20--89.19) 54.80 ± 12.18                                             738             55.19 (18.57--89.16) 56.30 ± 11.80                                            0.063
  Sex (male %)                 2376            1619 (68.1%)                                                     1638            1119 (68.3%)                                                                  738             500 (67.8%)                                                                   0.785
  Etiology of liver diseases                                                                                                                                                                                                                                                                                
  HBV (%)                      2376            920 (38.7%)                                                      1638            651 (39.7%)                                                                   738             269 (36.4%)                                                                   0.127
  HCV (%)                      2376            193 (8.1%)                                                       1638            136 (8.3%)                                                                    738             57 (7.7%)                                                                     0.632
  Alcohol abuse (%)            2376            904 (38%)                                                        1638            602 (36.8%)                                                                   738             302 (40.9%)                                                                   0.053
  Autoimmune (%)               2376            147 (6.2%)                                                       1638            83 (5.1%)                                                                     738             64 (8.7%)                                                                     **0.001**
  Other etiology (%)           2376            551 (23.2%)                                                      1638            379 (23.1%)                                                                   738             172 (23.3%)                                                                   0.928
  Ascites (%)                  2376            972 (40.9%)                                                      1638            556 (33.9%)                                                                   738             416 (56.4%)                                                                   **\<0.001**
  AUGIB (%)                    2376            663 (27.9%)                                                      1638            376 (23%)                                                                     738             287 (38.9%)                                                                   **\<0.001**
  Infection (%)                2376            517 (21.8%)                                                      1638            333 (20.3%)                                                                   738             184 (24.9%)                                                                   **0.012**
  Hb (g/l)                     2357            98 (23--218) 98.70 ± 30.84                                       1624            104 (23--218) 104.04 ± 30.91                                                  733             84 (27--176) 86.87 ± 27.19                                                    **\<0.001**
  WBC (10^9^/l)                2359            4 (0.5--53.6) 4.76 ± 3.44                                        1626            3.8 (0.5--33.5) 4.54 ± 3.08                                                   733             4.3 (0.5--53.6) 5.24 ± 4.08                                                   **\<0.001**
  PLT (10^9^/l)                2355            80 (3--1278) 105.23 ± 85.80                                      1623            81 (3--1278) 107.96 ± 86.92                                                   732             75 (5--842) 99.18 ± 83.00                                                     **0.002**
  TBIL (μmol/l)                2369            19.9 (1.9--809.8) 31.64 ± 47.53                                  1635            18.7 (2.4--809.8) 27.61 ± 39.47                                               734             22.6 (1.9--679.1) 40.63 ± 60.90                                               **\<0.001**
  ALB (g/l)                    2376            34.9 (9.6--56.2) 34.77 ± 6.22                                    1638            37.2 (31.7--56.2) 37.97 ± 4.22                                                738             28.75 (9.6--31.6) 27.67 ± 3.49                                                **\<0.001**
  ALT (U/l)                    2365            25.1 (4.23--1460.0) 39.60 ± 71.16                                1631            25 (4.47--1335.0) 39.11 ± 70.96                                               734             26 (4.23--1460.0) 40.70 ± 71.65                                               0.138
  AST (U/l)                    2366            33 (8--1366) 51.82 ± 78.29                                       1632            31 (8--1366) 47.83 ± 75.48                                                    734             39 (8--941) 60.69 ± 83.57                                                     **\<0.001**
  AKP (U/l)                    2362            88.83 (1.3--1338.0) 113.0 ± 93.62                                1629            86 (17--1388) 107.34 ± 85.45                                                  733             92.82 (1.3--980.0) 125.57 ± 108.65                                            **\<0.001**
  GGT (U/l)                    2361            47 (7.54--4562.0) 120.79 ± 236.93                                1628            45.27 (8--4562) 125.99 ± 263.27                                               733             51.97 (7.54--1779.18) 109.22 ± 163.49                                         0.369
  BUN (mmol/l)                 2321            5.39 (1.57--62.45) 6.77 ± 5.16                                   1603            5.28 (1.63--51.71) 6.43 ± 4.69                                                718             5.74 (1.57--62.45) 7.53 ± 6.01                                                **\<0.001**
  Scr (μmol/l)                 2321            60 (21--1473) 78.83 ± 109.66                                     1603            60 (21--1473) 77.31 ± 109.02                                                  718             59 (23--1353) 82.23 ± 111.07                                                  0.868
  K (mmol/l)                   2328            4 (2.13--7.24) 4.0 ± 0.49                                        1604            4 (2.48--7.24) 4.02 ± 0.46                                                    724             3.95 (2.13--6.00) 3.96 ± 0.55                                                 **0.001**
  Na (mmol/l)                  2328            139.4 (116.3--160.8) 138.94 ± 3.83                               1604            139.6 (117.9--153.9) 139.27 ± 3.60                                            724             138.8 (116.3--160.8) 138.23 ± 4.20                                            **\<0.001**
  Ammonia (μmol/l)             966             35 (2.2--317.0) 42.89 ± 35.14                                    618             33 (2.2--249.0) 38.17 ± 28.07                                                 348             39 (9--317) 51.26 ± 43.85                                                     **\<0.001**
  PT (seconds)                 2304            15.1 (10.3--51.5) 15.59 ± 3.15                                   1594            14.6 (10.4--51.0) 15.03 ± 2.74                                                710             16.2 (10.3--51.5) 16.83 ± 3.61                                                **\<0.001**
  APTT (seconds)               2302            40 (19.4--472.4) 41.37 ± 12.63                                   1592            39.5 (19.4--472.4) 40.46 ± 12.92                                              710             41.5 (23.1--180.0) 43.39 ± 11.72                                              **\<0.001**
  Child--Pugh score            2286            6 (5--13) 6.72 ± 1.62                                            1581            6 (5--12) 6.14 ± 1.27                                                         705             8 (6--13) 8.02 ± 1.59                                                         **\<0.001**
  MELD score                   2259            5.32 (−9.67 to 38.80) 6.08 ± 5.91                                1638            4.63 (−9.67 to 38.80) 5.19 ± 5.43                                             697             7.21 (−7.52 to 35.30) 8.06 ± 6.42                                             **\<0.001**
  Incidence of overt HE (%)    2376            113 (4.8%)                                                       1638            32 (2%)                                                                       738             81 (11%)                                                                      **\<0.001**

Bolded numerals indicate statistical significance.

AKP, alkaline phosphatase; ALB, albumin; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; AUGIB, acute upper gastrointestinal bleeding; BUN, blood urea nitrogen; GGT, gamma-glutamyl transpeptidase; Hb, hemoglobin; HBV, hepatic B virus; HCV, hepatic C virus; HE, hepatic encephalopathy; K, potassium; MELD, model for end-stage liver disease; Na, sodium; PLT, platelet count; PT, prothrombin time; Pts, patients; Scr, serum creatinine; TBIL, total bilirubin; WBC, white blood cell count.

Note: \*Continuous variables were reported as median (range) and mean ± standard deviation; categorical variables were reported as frequency (percentage).

In the univariate analysis, the statistically significant risk factors associated with the development of overt HE included age, ascites, AUGIB, infection, Hb, WBC, TBIL, ALB, AST, BUN, Scr, K, Na, ammonia, PT, APTT, Child--Pugh score, and MELD score ([Table 2](#table2-1756284819881302){ref-type="table"}). In the multivariate analysis, the independent risk factors associated with the development of overt HE included age (OR = 1.028, 95% CI: 1.003--1.052, *p* = 0.025), infection (OR = 2.668, 95%CI: 1.481--4.807, *p* = 0.001), ALB (OR = 0.878, 95% CI: 0.834--0.924, *p* \< 0.001), ammonia (OR = 1.029, 95%CI: 1.022--1.037, *p* \< 0.001), and PT (OR = 1.098, 95% CI: 1.016--1.187, *p* = 0.018; [Table 2](#table2-1756284819881302){ref-type="table"}).

###### 

Univariate and multivariate analyses of predictors associated with the development of overt HE.

![](10.1177_1756284819881302-table2)

  Variables (*n*)                                                             Univariate   Multivariate                                        
  --------------------------------------------------------------------------- ------------ -------------- ------------- ------- -------------- -------------
  Age (years)                                                                 1.021        1.004--1.037   **0.012**     1.028   1.003--1.052   **0.025**
  Sex (female *versus* male)                                                  1.044        0.694--1.571   0.836                                
  HBV (yes *versus* no)                                                       1.134        0.773--1.664   0.521                                
  HCV (yes *versus* no)                                                       1.646        0.922--2.941   0.092                                
  Alcohol abuse (yes *versus* no)                                             1.040        0.704--1.538   0.844                                
  Autoimmune (yes *versus* no)                                                1.185        0.512--2.744   0.692                                
  Other etiology (yes *versus* no)                                            1.262        0.784--2.031   0.338                                
  Ascites (yes *versus* no)                                                   2.660        1.796--3.938   **\<0.001**   1.136   0.656--1.967   0.650
  AUGIB (yes *versus* no)                                                     1.694        1.148--2.500   **0.008**     1.888   0.927--3.843   0.080
  Infection (yes *versus* no)                                                 2.318        1.565--3.435   **\<0.001**   2.668   1.481--4.807   **0.001**
  Hb (g/l)                                                                    0.991        0.985--0.997   **0.005**     0.997   0.985--1.009   0.621
  WBC (10^9^/l)                                                               1.090        1.050--1.132   **\<0.001**   1.032   0.962--1.108   0.377
  PLT (10^9^/l)                                                               0.997        0.995--1.000   0.086                                
  TBIL (μmol/l)                                                               1.006        1.004--1.009   **\<0.001**   1.002   0.999--1.005   0.205
  ALB (g/l)                                                                   0.853        0.826--0.880   **\<0.001**   0.878   0.834--0.924   **\<0.001**
  ALT (U/l)                                                                   1.001        1.000--1.003   0.078                                
  AST (U/l)                                                                   1.002        1.000--1.003   **0.016**     1.000   0.998--1.003   0.889
  AKP (U/l)                                                                   1.000        0.998--1.002   0.901                                
  GGT (U/l)                                                                   1.000        0.999--1.001   0.893                                
  BUN (mmol/l)                                                                1.072        1.049--1.095   **\<0.001**   1.073   0.991--1.162   0.810
  Scr (μmol/l)                                                                1.001        1.000--1.002   **0.043**     0.998   0.994--1.003   0.463
  K (mmol/l)                                                                  1.677        1.169--2.407   **0.005**     1.507   0.934--2.433   0.093
  Na (mmol/l)                                                                 0.938        0.897--0.981   **0.005**     1.044   0.977--1.116   0.205
  Ammonia (μmol/l)                                                            1.033        1.026--1.039   **\<0.001**   1.029   1.022--1.037   **\<0.001**
  PT (seconds)                                                                1.170        1.122--1.220   **\<0.001**   1.098   1.016--1.187   **0.018**
  APTT (seconds)                                                              1.013        1.001--1.024   **0.029**     0.991   0.965--1.017   0.474
  Child--Pugh score^[\*](#table-fn4-1756284819881302){ref-type="table-fn"}^   1.781        1.605--1.977   **\<0.001**                          
  MELD score^[\*](#table-fn4-1756284819881302){ref-type="table-fn"}^          1.137        1.109--1.166   **\<0.001**                          

Bolded numerals indicate statistical significance.

Child--Pugh and MELD scores, which are complex variables comprising many clinically significant variables, were excluded in the multivariate analysis.

AKP, alkaline phosphatase; ALB, albumin; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; AUGIB, acute upper gastrointestinal bleeding; BUN, blood urea nitrogen; CI, confidence interval; DBIL, direct bilirubin; GGT, gamma-glutamyl transpeptidase; Hb, hemoglobin; HBV, hepatic B virus; HCV, hepatic C virus; HE, hepatic encephalopathy; IBIL, indirect bilirubin; INR, international normalization ratio; K, potassium; MELD, model for end-stage liver disease; Na, sodium; OR, odds ratio; PLT, platelet count; PT, prothrombin time; RBC, red blood cell count; Scr, serum creatinine; TBIL, total bilirubin; WBC, white blood cell count.

AUC of serum ALB level for predicting the development of overt HE was 0.770 (95% CI: 0.752--0.787, *p* \< 0.0001; [Figure 2](#fig2-1756284819881302){ref-type="fig"}). The best cut-off value was ⩽31.6 g/l with a sensitivity of 71.68% and a specificity of 70.97%. According to the cut-off value, 2376 patients were divided into high (*n* = 1638) and low (*n* = 738) serum ALB level groups ([Table 1](#table1-1756284819881302){ref-type="table"}). The low-serum-ALB-level group had a significantly higher prevalence of ascites (*p* \< 0.001), AUGIB (*p* \< 0.001), and infection (*p* = 0.012) than the high-serum-ALB-level group. Hb, WBC, PLT, TBIL, ALB, AST, AKP, BUN, K, Na, ammonia, PT, APTT, Child--Pugh score, and MELD score were significantly different between high- and low-serum-ALB-level groups (*p* \< 0.05, in all comparisons). The low-serum-ALB-level group had a significantly higher incidence of overt HE during hospitalization (11.00% *versus* 2.00%, *p* \< 0.001; [Table 1](#table1-1756284819881302){ref-type="table"}). Kaplan--Meier curve analysis also found that the low-serum-ALB-level group had a significantly higher cumulative rate of overt HE (*p* \< 0.001; [Figure 3](#fig3-1756284819881302){ref-type="fig"}).

![ROC curve of ALB level for predicting the development of overt HE.\
ALB, albumin; HE, hepatic encephalopathy; ROC, receiver operating characteristic.](10.1177_1756284819881302-fig2){#fig2-1756284819881302}

![Cumulative rate of overt HE between high and low-ALB-level groups.\
ALB, albumin; HE, hepatic encephalopathy.](10.1177_1756284819881302-fig3){#fig3-1756284819881302}

Association of serum ALB level with mortality of patients with overt HE during hospitalizations {#section12-1756284819881302}
-----------------------------------------------------------------------------------------------

A total of 183 cirrhotic patients with overt HE were included ([Figure 1](#fig1-1756284819881302){ref-type="fig"}). Baseline characteristics are described in [Table 3](#table3-1756284819881302){ref-type="table"}. Median age was 57.17 years (range: 27.49--95.13), and 134 (73.20%) patients were male. Median ALB level was 30.40 g/l (range: 12.40--48.90). Median Child--Pugh and MELD scores were 9 (range: 6--15) and 9.49 (range: --1.73--51.64), respectively. Among them, in-hospital mortality was 10.9% (20/183).

###### 

Mortality of overt HE: difference between high-ALB-level (\>22.8 g/l) and low-ALB-level (⩽22.8 g/l) groups.

![](10.1177_1756284819881302-table3)

  Variables                    Patients, *n*   Overall[\*](#table-fn12-1756284819881302){ref-type="table-fn"}   Patients, *n*   ALB \> 22.8g/l group[\*](#table-fn12-1756284819881302){ref-type="table-fn"}   Patients, *n*   ALB ⩽ 22.8g/l group[\*](#table-fn12-1756284819881302){ref-type="table-fn"}   *p* value
  ---------------------------- --------------- ---------------------------------------------------------------- --------------- ----------------------------------------------------------------------------- --------------- ---------------------------------------------------------------------------- -------------
  Age, years                   183             57.17 (27.49--95.13) 58.21 ± 10.62                               164             57.26 (27.49--95.13) 58.35 ± 10.56                                            19              56.35 (30.78--78.81) 56.97 ± 11.32                                           0.605
  Sex (male %)                 183             134 (73.2%)                                                      164             118 (72%)                                                                     19              16 (84.2%)                                                                   0.253
  Etiology of liver diseases                                                                                                                                                                                                                                                                               
  HBV (%)                      183             58 (31.7%)                                                       164             50 (30.5%)                                                                    19              8 (42.1%)                                                                    0.303
  HCV (%)                      183             15 (8.2%)                                                        164             15 (9.1%)                                                                     19              0 (0%)                                                                       0.169
  Alcohol abuse (%)            183             86 (47.6%)                                                       164             78 (47.6%)                                                                    19              8 (42.1%)                                                                    0.652
  Autoimmune (%)               183             8 (4.4%)                                                         164             8 (4.9%)                                                                      19              0 (0%)                                                                       0.325
  Other etiology (%)           183             35 (19.1%)                                                       164             31 (18.9%)                                                                    19              4 (21.1%)                                                                    0.822
  Ascites (%)                  183             99 (54.1%)                                                       164             83 (50.6%)                                                                    19              16 (84.2%)                                                                   **0.005**
  AUGIB (%)                    183             60 (32.8%)                                                       164             51 (31.1%)                                                                    19              9 (47.4%)                                                                    0.153
  Infection (%)                183             37 (20.2%)                                                       164             31 (18.9%)                                                                    19              6 (31.6%)                                                                    0.193
  Hb (g/l)                     181             96 (37--180) 99.47 ± 27.45                                       162             98 (37--180) 101.46 ± 27.65                                                   19              81 (49--116) 82.34 ± 18.67                                                   **0.003**
  WBC (10^9^/l)                181             4.7 (1.1--46.1) 6.25 ± 5.09                                      162             4.7 (1.1--46.1) 6.05 ± 5.00                                                   19              6 (2.0--25.3) 7.9 ± 5.62                                                     0.088
  PLT (10^9^/l)                180             74.5 (16--391) 85.86 ± 57.29                                     161             75 (17--391) 87.84 ± 58.85                                                    19              68 (16--158) 69.05 ± 38.93                                                   0.244
  TBIL (μmol/l)                183             37.3 (3.6--707.7) 58.83 ± 84.90                                  164             36.1 (3.6--707.7) 54.67 ± 85.39                                               19              66.5 (24.0--255.5) 94.75 ± 72.99                                             **0.001**
  ALB (g/l)                    183             30.4 (12.4--48.9) 30.22 ± 6.11                                   164             31.2 (23.0--48.9) 31.47 ± 5.01                                                19              21.3 (12.4--22.8) 19.36 ± 3.40                                               **\<0.001**
  ALT (U/l)                    182             28 (8--1064) 45.56 ± 91.53                                       163             27 (8--1064) 45.26 ± 96.13                                                    19              40 (16--131) 48.21 ± 32.72                                                   **0.027**
  AST (U/l)                    182             42 (9--2454) 94.62 ± 246.32                                      163             40 (9--2454) 88.73 ± 241.66                                                   19              68 (19--1293) 145.11 ± 285.52                                                **0.010**
  AKP (U/l)                    181             92 (34--457) 113.80 ± 70.40                                      163             93 (34--457) 114.52 ± 72.00                                                   18              83.5 (47.0--205.4) 107.25 ± 54.96                                            0.763
  GGT (U/l)                    181             46 (7--1102) 109.02 ± 182.57                                     163             47 (7--1055) 107.78 ± 173.49                                                  18              33.5 (14--1102) 120.28 ± 256.82                                              0.306
  BUN (mmol/l)                 176             6.56 (1.58--61.01) 8.98 ± 7.99                                   158             6.19 (2.32--61.01) 8.82 ± 8.04                                                18              8.08 (1.58--29.31) 10.39 ± 7.59                                              0.181
  Scr (μmol/l)                 176             61 (24--729) 79.29 ± 68.49                                       158             60 (24--729) 76.72 ± 68.80                                                    18              77.5 (36--262) 101.89 ± 63.05                                                **0.049**
  K (mmol/l)                   180             4.09 (2.25--7.87) 4.18 ± 0.74                                    162             4.05 (2.25--7.87) 4.14 ± 0.72                                                 18              4.46 (3.24--6.36) 4.51 ± 0.86                                                0.063
  Na (mmol/l)                  181             138 (116.4--147.2) 137.28 ± 5.35                                 162             138.1 (116.4--147.2) 137.52 ± 5.20                                            19              136.9 (121.9--144.8) 135.25 ± 6.30                                           0.145
  Ammonia (μmol/l)             175             79 (9--480) 88.39 ± 55.73                                        156             79.5 (9--480) 88.00 ± 54.70                                                   19              72 (9--283) 91.57 ± 65.18                                                    0.838
  PT (seconds)                 178             17.3 (12.2--94.6) 18.81 ± 7.15                                   161             17.1 (12.2--36.4) 17.86 ± 3.45                                                17              22.1 (16.6--94.6) 27.85 ± 18.73                                              **\<0.001**
  APTT (seconds)               177             44.4 (29.1--180.0) 46.63 ± 14.28                                 160             43.5 (29.1--75.4) 44.55 ± 8.27                                                17              55 (42.1--180.0) 66.28 ± 33.32                                               **\<0.001**
  Child--Pugh score            177             9 (6--15) 9.30 ± 2.19                                            160             6 (6--15) 9.01 ± 2.01                                                         17              12 (8--15) 12.06 ± 1.89                                                      **\<0.001**
  MELD score                   173             9.49 (−1.73 to 51.64) 11.34 ± 7.75                               156             8.93 (−1.73 to 36.99) 10.30 ± 6.51                                            17              22.39 (4.18--51.64) 20.92 ± 11.29                                            **\<0.001**
  In-hospital death (%)        183             20 (10.9%)                                                       164             11 (6.7%)                                                                     19              9 (47.4%)                                                                    **\<0.001**

Bolded numerals indicate statistical significance.

AKP, alkaline phosphatase; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; APTT, activated partial thromboplastin time; AUGIB, acute upper gastrointestinal bleeding; BUN, blood urea nitrogen; Hb, hemoglobin; HBV, hepatic B virus; HCV, hepatic C virus; K, potassium; MELD, model for end-stage liver disease; Na, sodium; PLT, platelet count; PT, prothrombin time; Pts, patients; TBIL, total bilirubin; GGT, gamma-glutamyl transpeptidase; Scr, serum creatinine; WBC, white blood cell count.

Note: \*Continuous variables were reported as median (range) and mean ± standard deviation; categorical variables were reported as frequency (percentage).

In the univariate analysis, the statistically significant risk factors associated with the in-hospital death of patients with overt HE included WBC, TBIL, ALB, AST, BUN, K, APTT, Child--Pugh score, and MELD score ([Table 4](#table4-1756284819881302){ref-type="table"}). In the multivariate analysis, the independent risk factors associated with the in-hospital death of patients with overt HE included WBC (OR = 1.169, 95% CI: 1.037--1.317, *p* = 0.011), TBIL (OR = 1.006, 95% CI: 1.001--1.011, *p* = 0.018), and ALB (OR = 0.864, 95% CI: 0.771--0.967, *p* \< 0.001; [Table 4](#table4-1756284819881302){ref-type="table"}).

###### 

Univariate and multivariate analyses of predictors associated with the in-hospital death from overt HE.

![](10.1177_1756284819881302-table4)

  Variables (*n*)                                                             Univariate   Multivariate                                         
  --------------------------------------------------------------------------- ------------ --------------- ------------- ------- -------------- -----------
  Age (years)                                                                 1.028        0.985--1.073    0.197                                
  Sex (female *versus* male)                                                  1.109        0.381--3.232    0.849                                
  HBV (yes *versus* no)                                                       1.445        0.499--4.188    0.497                                
  HCV (yes *versus* no)                                                       1.282        0.268--6.143    0.756                                
  Alcohol Abuse (yes *versus* no)                                             1.376        0.535--3.545    0.508                                
  Autoimmune (yes *versus* no)                                                1.173        0.137--10.057   0.884                                
  Other etiology (yes *versus* no)                                            1.478        0.498--4.382    0.481                                
  Ascites (yes *versus* no)                                                   2.141        0.784--5.847    0.1371                               
  AUGIB (yes *versus* no)                                                     1.797        0.701--4.605    0.222                                
  Infection (yes *versus* no)                                                 2.387        0.878--6.493    0.088                                
  Hb (g/l)                                                                    0.985        0.967--1.004    0.114                                
  WBC (10^9^/l)                                                               1.222        1.107--1.348    **\<0.001**   1.169   1.037--1.317   **0.011**
  PLT (10^9^/l)                                                               0.999        0.990--1.007    0.796                                
  TBIL (μmol/l)                                                               1.007        1.002--1.012    **0.007**     1.006   1.001--1.011   **0.018**
  ALB (g/l)                                                                   0.852        0.782--0.927    **\<0.001**   0.864   0.771--0.967   **0.011**
  ALT (U/l)                                                                   1.005        1.000--1.011    0.056                                
  AST (U/l)                                                                   1.002        1.000--1.003    **0.027**     1.000   0.998--1.002   0.882
  AKP (U/l)                                                                   0.994        0.985--1.004    0.232                                
  GGT (U/l)                                                                   1.000        0.998--1.003    0.705                                
  BUN (mmol/l)                                                                1.060        1.014--1.108    **0.010**     1.075   0.974--1.185   0.152
  Scr (μmol/l)                                                                1.005        1.000--1.011    0.058                                
  K (mmol/l)                                                                  1.930        1.119--3.328    **0.018**     0.620   0.223--1.720   0.358
  Na (mmol/l)                                                                 0.932        0.861--1.009    0.080                                
  Ammonia (μmol/l)                                                            1.003        0.995--1.010    0.474                                
  PT (seconds)                                                                1.060        0.995--1.128    0.071                                
  APTT (seconds)                                                              1.057        1.016--1.098    **0.006**     1.014   0.965--1.067   0.576
  Child--Pugh score^[\*](#table-fn9-1756284819881302){ref-type="table-fn"}^   1.459        1.171--1.818    **0.001**                            
  MELD score^[\*](#table-fn9-1756284819881302){ref-type="table-fn"}^          1.145        1.077--1.217    **\<0.001**                          

Bolded numerals indicate statistical significance.

Child--Pugh and MELD scores, which are complex variables comprising many clinically significant variables, were excluded in the multivariate analysis.

AKP, alkaline phosphatase; ALB, albumin; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; AUGIB, acute upper gastrointestinal bleeding; BUN, blood urea nitrogen; CI, confidence interval; GGT, gamma-glutamyl transpeptidase; Hb, hemoglobin; HBV, hepatic B virus; HCV, hepatic C virus; HE, hepatic encephalopathy; K, potassium; MELD, model for end-stage liver disease; Na, sodium; OR, odds ratio; PLT, platelet count; PT, prothrombin time; Scr, serum creatinine; TBIL, total bilirubin; WBC, white blood cell count.

AUC of serum ALB level for predicting the in-hospital death of patients with overt HE was 0.737 (95% CI: 0.667--0.799, *p* = 0.0001). The best cut-off value was ⩽22.8 g/l, with a sensitivity of 45.0% and a specificity of 93.9% ([Figure 4](#fig4-1756284819881302){ref-type="fig"}). According to the cut-off value, 183 patients were divided into high (*n* = 164) and low (*n* = 19) serum ALB level groups ([Table 3](#table3-1756284819881302){ref-type="table"}). The low-serum-ALB-level group had a significantly higher prevalence of ascites (*p* = 0.005) than the high-serum-ALB-level group. Hb, TBIL, ALB, AST, Scr, PT, APTT, Child--Pugh score, and MELD score were significantly different between high- and low-ALB-level groups (*p* \< 0.05, in all comparisons). The low-serum-ALB-level group had a significantly higher mortality of overt HE during hospitalization (47.4% *versus* 6.7%, *p* \< 0.001; [Table 3](#table3-1756284819881302){ref-type="table"}). Kaplan--Meier curve analysis also found that the low-serum-ALB-level group had a significantly higher cumulative rate of mortality (*p* \< 0.001; [Figure 5](#fig5-1756284819881302){ref-type="fig"}).

![ROC curve of ALB level for predicting the in-hospital death from overt HE.\
ALB, albumin; HE, hepatic encephalopathy; ROC, receiver operating characteristic.](10.1177_1756284819881302-fig4){#fig4-1756284819881302}

![Cumulative rate of mortality between high and low-ALB-level groups.\
ALB, albumin.](10.1177_1756284819881302-fig5){#fig5-1756284819881302}

Discussion {#section13-1756284819881302}
==========

Our study confirmed that serum ALB level was significantly associated with the development of overt HE in liver cirrhosis during hospitalization. As compared with those with serum ALB level \> 31.6 g/l, patients with serum ALB level ⩽ 31.6 g/l had a 5.5-fold increased risk of developing overt HE in cirrhotic patients. Our study also found that the serum ALB level was significantly associated with the in-hospital death of cirrhotic patients with overt HE. As compared with those with serum ALB level \> 22.8 g/l, patients with serum ALB level ⩽ 22.8 g/l had a nearly 7-fold increased risk of in-hospital death in cirrhotic patients with overt HE.

Serum ALB level and development of HE {#section14-1756284819881302}
-------------------------------------

Previous studies have explored the epidemiology of HE in cirrhosis and risk factors associated with development of HE. Among the studies we reviewed ([Supplementary Table 1](http://journals.sagepub.com/doi/suppl/10.1177/1756284819881302)), five studies were cross-sectional studies, four were prospective cohort studies, three were retrospective cohort studies, and one was a case-control study. Among them, eight studies explored the association of serum ALB level with development of HE, and six and two studies focused on minimal/covert HE and overt HE, respectively. All of the eight studies performed the univariate analyses and seven of them reported that serum ALB level was a statistically significant risk factor associated with development of HE; six studies performed the multivariate analyses and four of them reported that serum ALB level was an independent risk factor associated with development of HE. Similarly, our study also suggested serum ALB level was a statistically significant risk factor associated with development of HE, regardless of univariate or multivariate analyses.

Compared with previous studies, our study had particular features. First, our study had a larger number of cirrhotic patients than previous studies. Second, Child--Pugh and MELD scores, which are complex variables comprising many clinically significant variables, were excluded in our multivariate analysis. By contrast, the studies by Bhanji and colleagues,^[@bibr15-1756284819881302]^ Bale and colleagues,^[@bibr16-1756284819881302]^ and Nardelli and colleagues^[@bibr17-1756284819881302]^ included Child--Pugh score with or without MELD score in their multivariate analyses. This might affect the statistical results because the two scores had a potential collinearity with many variables for assessing liver dysfunction. Third, the selection of the target population was more appropriate. The patients receiving HA infusion, which would affect serum ALB level, were excluded from our study. Although serum ALB level was also an independent risk factor in the studies of Zhang and colleagues,^[@bibr18-1756284819881302]^ Nardelli and colleagues,^[@bibr17-1756284819881302]^ Tapper and colleagues,^[@bibr19-1756284819881302]^ and Labenz and colleagues,^[@bibr20-1756284819881302]^ none of them had excluded the patients receiving HA infusion. Fourth, the incidence of HE in our study was 4.8% and significantly lower than previous studies in which the incidence of HE was 20.8--45.9% ([Supplementary Table 1](http://journals.sagepub.com/doi/suppl/10.1177/1756284819881302)). This could be explained by the occurrence of HE events observed during hospitalization in our study; by comparison, the occurrence of HE was observed during the long-term follow up in previous studies (length of follow up: 6 months to 5 years). Additionally, we evaluated overt HE, and did not consider minimal HE. Fifth, we performed the ROC curve analysis and identified the best cut-off value of serum ALB level for predicting the development of overt HE.

Serum ALB level and death of cirrhotic patients with HE {#section15-1756284819881302}
-------------------------------------------------------

We also reviewed previous studies looking at mortality and risk factors associated with death of cirrhotic patients with HE ([Supplementary Table 2](http://journals.sagepub.com/doi/suppl/10.1177/1756284819881302)). Among the five reviewed studies, four studies were retrospective cohort studies and one study was a prospective cohort study. The mortality of HE in the studies of Bustamante and colleagues,^[@bibr21-1756284819881302]^ Fichet and colleagues,^[@bibr22-1756284819881302]^ Cordoba and colleagues,^[@bibr23-1756284819881302]^ and Cui and colleagues^[@bibr24-1756284819881302]^ were 73.9%, 58.6%, 42.8%, and 67.7%, respectively, which was higher than that in our study (10.9%). This could be because the death event during hospitalization was observed in our study; by comparison, the death event during the long-term follow up was observed in previous studies (length of follow up: 3 months to 1 year). Notably, in the study by Jeong and colleagues,^[@bibr25-1756284819881302]^ where the length of follow up was 30 days, the mortality of HE was 6.7%, which was similar to that in our study. All of the five reviewed studies explored the association of serum ALB level with death from overt HE. Four studies reported the statistical results from univariate analyses and two studies showed that serum ALB level was a statistically significant risk factor associated with death from HE. Five studies reported the statistical results from multivariate analyses and one study showed that serum ALB level was an independent risk factor associated with death from HE. Notably, in the study of Cui and colleagues,^[@bibr24-1756284819881302]^ serum ALB level was not associated with death from HE in both univariate and multivariate analyses; this was because all patients with low serum ALB level received HA infusion.

Timing of HA infusion for preventing from development and death from HE in cirrhosis {#section16-1756284819881302}
------------------------------------------------------------------------------------

Early studies explored the role of HA infusion in the prognosis of hospital-admission patients. In 1998, a systematic review of randomized control trials^[@bibr26-1756284819881302]^ showed that HA infusion might increase the mortality of critically ill patients. This conclusion had led to a significant decrease in the application of HA.^[@bibr27-1756284819881302]^ By contrast, in 2011, an updated systematic review did not show that HA infusion increased the risk of death.^[@bibr28-1756284819881302]^ Recently, more and more studies have supported the use of HA infusion in improving the prognosis of patients with cirrhosis and its complications.^[@bibr11-1756284819881302],[@bibr29-1756284819881302]^ However, the timing of HA infusion in cirrhotic patients remained unclear.

Conventionally, hypoalbuminemia in adults is defined by a decreased serum ALB level of \<35 g/l, and clinically significant hypoalbuminemia is probably identified by serum ALB level \< 25 g/l.^[@bibr30-1756284819881302]^ Current guidelines suggested that the timing of HA infusion should be a serum ALB level of \<25 g/l or \<20 g/l in various types of patients.^[@bibr31-1756284819881302],[@bibr32-1756284819881302]^ But it should be noted that HA infusion can be commenced earlier in cirrhotic patients with hypovolemia and refractory ascites; even those with a serum ALB level of \>25 g/l.^[@bibr31-1756284819881302]^

The cut-off value of serum ALB level for predicting the risk of death was often heterogeneous among the study population, suggesting the heterogeneous timing of HA infusion in different clinical settings. In patients with major abdominal procedures or kidney cancer, serum ALB level \< 32 g/l was associated with an increased risk for complications or death.^[@bibr33-1756284819881302],[@bibr34-1756284819881302]^ In patients with hilar cholangiocarcinoma, serum ALB level \< 30 g/l was significantly associated with worse outcomes.^[@bibr35-1756284819881302]^ In cirrhotic patients with spontaneous bacterial peritonitis, serum ALB level \< 28.5 g/l was associated with worse long-term survival.^[@bibr36-1756284819881302]^ By comparison, our study showed that serum ALB level ⩽ 31.6 g/l might be associated with higher risk of development of HE, and serum ALB level ⩽ 22.8 g/l might be associated with higher risk of in-hospital death from HE. Therefore, we proposed the following assumptions: as for the patients without HE at admission, physicians might consider serum ALB level ⩽ 31.6 g/l as a threshold of HA infusion for prevention of overt HE; as for patients with HE at admission, physicians might consider serum ALB level ⩽ 22.8 g/l as a threshold of HA infusion for preventing the in-hospital death from HE. Certainly, these considerations should be confirmed in future cohort studies regarding albumin infusion for HE.

Limitations {#section17-1756284819881302}
-----------

Our study has some limitations. First, our study is a retrospective cohort study in which some patients' data were missing. Second, we did not consider minimal HE. Third, we focused on the in-hospital outcomes, but not long-term outcomes. Fourth, we cannot explore the mechanism of serum ALB level in predicting the development of, and death from, overt HE.

In conclusion, a decrease of serum ALB level may play an important role in predicting the development of, and death from, overt HE during hospitalization in liver cirrhosis. A serum ALB level of ⩽31.6 g/l may be associated with higher risk for development of overt HE in cirrhosis. A serum ALB level of ⩽22.8 g/l may be associated with higher risk for death from overt HE. However, these findings should be externally validated in different populations. Whether these cut-off values can be considered as the thresholds for HA infusion for preventing the development of, and death from, overt HE in cirrhotic patients should be further explored.
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